

Danial E Baker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4600281/publications.pdf>

Version: 2024-02-01

313
papers

1,256
citations

516215

16
h-index

525886

27
g-index

358
all docs

358
docs citations

358
times ranked

1643
citing authors

#	ARTICLE	IF	CITATIONS
1	Miglitol: Assessment of its Role in the Treatment of Patients with Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2000, 34, 1291-1301.	0.9	89
2	Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2006, 28, 652-665.	1.1	82
3	Phosphodiesterase 5 Inhibitors for Erectile Dysfunction. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1286-1295.	0.9	69
4	Rationale for using serotonergic agents to treat irritable bowel syndrome. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 700-711.	0.5	52
5	Insulin Glargine: A New Basal Insulin. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1019-1027.	0.9	50
6	Insulin glargine. <i>Clinical Therapeutics</i> , 2001, 23, 1938-1957.	1.1	43
7	Tofacitinib. <i>Hospital Pharmacy</i> , 2013, 48, 413-424.	0.4	29
8	Nateglinide Therapy for Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1426-1434.	0.9	25
9	Cangrelor. <i>Hospital Pharmacy</i> , 2015, 50, 922-929.	0.4	24
10	Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4, 196-210.	0.6	24
11	Vitamin and Mineral Supplementation in Patients with Diabetes Mellitus. <i>The Diabetes Educator</i> , 1992, 18, 420-427.	2.6	22
12	Rifaximin: a nonabsorbed oral antibiotic. <i>Reviews in Gastroenterological Disorders</i> , 2005, 5, 19-30.	0.6	22
13	Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. <i>Reviews in Gastroenterological Disorders</i> , 2003, 3, 93-109.	0.6	19
14	Pentoxifylline: A New Agent for Intermittent Claudication. <i>Drug Intelligence & Clinical Pharmacy</i> , 1985, 19, 345-348.	0.4	18
15	Inhaled dry powder insulin for the treatment of diabetes mellitus. <i>Clinical Therapeutics</i> , 2007, 29, 795-813.	1.1	18
16	The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4, 86-91.	0.6	18
17	Dimethyl Fumarate. <i>Hospital Pharmacy</i> , 2013, 48, 668-679.	0.4	17
18	Natalizumab: overview of its pharmacology and safety. <i>Reviews in Gastroenterological Disorders</i> , 2007, 7, 38-46.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Apremilast. Hospital Pharmacy, 2014, 49, 752-762.	0.4	14
20	Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum. Reviews in Gastroenterological Disorders, 2003, 3, 31-8.	0.6	14
21	Naloxegol. Annals of Pharmacotherapy, 2015, 49, 360-365.	0.9	13
22	Uridine Triacetate. Hospital Pharmacy, 2016, 51, 484-488.	0.4	13
23	Sugammadex. Hospital Pharmacy, 2016, 51, 585-596.	0.4	13
24	Teriflunomide. Hospital Pharmacy, 2013, 48, 231-240.	0.4	12
25	Defibrotide. Hospital Pharmacy, 2016, 51, 847-854.	0.4	12
26	Lidocaine/Tetracaine Patch. Hospital Pharmacy, 2006, 41, 265-273.	0.4	11
27	Medication Alert Fatigue: The Potential for Compromised Patient Safety. Hospital Pharmacy, 2009, 44, 460-461.	0.4	11
28	Prothrombin Complex Concentrate. Hospital Pharmacy, 2013, 48, 951-957.	0.4	11
29	Thrombin, Topical (Recombinant). Hospital Pharmacy, 2008, 43, 577-585.	0.4	10
30	Apixaban. Hospital Pharmacy, 2013, 48, 494-511.	0.4	10
31	Ferric Carboxymaltose. Hospital Pharmacy, 2014, 49, 52-69.	0.4	10
32	Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Reviews in Gastroenterological Disorders, 2003, 3, 150-7.	0.6	10
33	Clevidipine Butyrate Injectable Emulsion. Hospital Pharmacy, 2008, 43, 903-912.	0.4	9
34	Conjugated Estrogens and Bazedoxifene. Hospital Pharmacy, 2014, 49, 273-283.	0.4	9
35	Eteplirsen. Hospital Pharmacy, 2017, 52, 302-305.	0.4	9
36	Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Reviews in Gastroenterological Disorders, 2002, 2, 20-33.	0.6	9

#	ARTICLE	IF	CITATIONS
37	MMX mesalamine. Reviews in Gastroenterological Disorders, 2006, 6, 146-52.	0.6	9
38	Therapeutic Advances in the Prevention of Hepatitis B: Yeast-Derived Recombinant Hepatitis B Vaccines. DICP: the Annals of Pharmacotherapy, 1991, 25, 617-627.	0.2	8
39	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Tablets. Hospital Pharmacy, 2013, 48, 48-56.	0.4	8
40	Irinotecan Liposome Injection. Hospital Pharmacy, 2017, 52, 144-150.	0.4	8
41	Coagulation Factor Xa (Recombinant), Inactivated-zhzo (Andexanet Alfa). Hospital Pharmacy, 2018, 53, 286-291.	0.4	8
42	Selected Topics in Drug Information Access and Practice: An Update. Annals of Pharmacotherapy, 1994, 28, 1389-1394.	0.9	7
43	Sofosbuvir. Hospital Pharmacy, 2014, 49, 466-478.	0.4	7
44	Sacubitril/Valsartan. Hospital Pharmacy, 2015, 50, 1025-1036.	0.4	7
45	Sildenafil (Viagra) for the Treatment of Erectile Dysfunction in Men With Diabetes. The Diabetes Educator, 1999, 25, 79-89.	2.6	6
46	Dalbavancin. Hospital Pharmacy, 2014, 49, 851-861.	0.4	6
47	Secukinumab. Hospital Pharmacy, 2015, 50, 714-727.	0.4	6
48	Elbasvir/Grazoprevir. Hospital Pharmacy, 2016, 51, 665-686.	0.4	6
49	Formulary Drug Review: Edaravone. Hospital Pharmacy, 2017, 52, 732-736.	0.4	6
50	Formulary Drug Review: Betrixaban. Hospital Pharmacy, 2018, 53, 29-37.	0.4	6
51	Baloxavir Marboxil. Hospital Pharmacy, 2019, 54, 165-169.	0.4	6
52	Alogliptin. Hospital Pharmacy, 2013, 48, 580-592.	0.4	5
53	Canagliflozin. Hospital Pharmacy, 2013, 48, 855-867.	0.4	5
54	Has the Time Come for "Medication Tourism"? Hospital Pharmacy, 2014, 49, 999-1000.	0.4	5

#	ARTICLE	IF	CITATIONS
55	Edoxaban. Hospital Pharmacy, 2015, 50, 619-634.	0.4	5
56	Ledipasvir/Sofosbuvir. Hospital Pharmacy, 2015, 50, 224-234.	0.4	5
57	Zika Virus and the Media. Hospital Pharmacy, 2016, 51, 275-276.	0.4	5
58	Sodium Zirconium Cyclosilicate. Hospital Pharmacy, 2019, 54, 12-19.	0.4	5
59	Intravenous proton pump inhibitors. Reviews in Gastroenterological Disorders, 2006, 6, 22-34.	0.6	5
60	Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction. Reviews in Gastroenterological Disorders, 2009, 9, E84-93.	0.6	5
61	Pneumococcal 7-Valent Conjugate Vaccine. Hospital Pharmacy, 2000, 35, 750-760.	0.4	4
62	Use of Color on Pharmaceutical Labels and Packaging. Hospital Pharmacy, 2005, 40, 296-297.	0.4	4
63	Certolizumab pegol for the treatment of Crohn's disease. Expert Review of Clinical Immunology, 2009, 5, 683-691.	1.3	4
64	Doxylamine Succinate/Pyridoxine Hydrochloride. Hospital Pharmacy, 2013, 48, 762-766.	0.4	4
65	Tedizolid Phosphate. Hospital Pharmacy, 2014, 49, 961-971.	0.4	4
66	Umeclidinium Bromide and Vilanterol Trifenatate Inhalation Powder. Hospital Pharmacy, 2014, 49, 554-562.	0.4	4
67	Ferric Citrate. Hospital Pharmacy, 2015, 50, 139-151.	0.4	4
68	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Hospital Pharmacy, 2015, 50, 396-415.	0.4	4
69	Daclizumab. Hospital Pharmacy, 2016, 51, 928-939.	0.4	4
70	Erenumab-aooe. Hospital Pharmacy, 2018, 53, 363-368.	0.4	4
71	Aliskiren. Hospital Pharmacy, 2007, 42, 737-750.	0.4	3
72	Ambrisentan. Hospital Pharmacy, 2007, 42, 1145-1154.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Hydroxyethyl Starch 130/0.4. Hospital Pharmacy, 2008, 43, 396-408.	0.4	3
74	Doripenem for Injection. Hospital Pharmacy, 2008, 43, 210-221.	0.4	3
75	Acetaminophen: Is it Time for a Change in Utilization to Decrease the Risk of Hepatotoxicity?. Hospital Pharmacy, 2009, 44, 843-845.	0.4	3
76	Milnacipran. Hospital Pharmacy, 2009, 44, 604-618.	0.4	3
77	Antithrombin (Recombinant). Hospital Pharmacy, 2009, 44, 785-793.	0.4	3
78	Fospropofol Disodium. Hospital Pharmacy, 2009, 44, 242-250.	0.4	3
79	Linacotide. Hospital Pharmacy, 2013, 48, 143-152.	0.4	3
80	Dapagliflozin. Hospital Pharmacy, 2014, 49, 647-662.	0.4	3
81	Netupitant/Palonosetron. Hospital Pharmacy, 2015, 50, 310-328.	0.4	3
82	Mepolizumab. Hospital Pharmacy, 2016, 51, 405-414.	0.4	3
83	Patiomer. Hospital Pharmacy, 2016, 51, 328-336.	0.4	3
84	Lixisenatide. Hospital Pharmacy, 2017, 52, 65-80.	0.4	3
85	High Drug Prices: So who is to Blame?. Hospital Pharmacy, 2017, 52, 5-6.	0.4	3
86	Zoster Vaccine Recombinant, Adjuvanted. Hospital Pharmacy, 2018, 53, 136-141.	0.4	3
87	Omadacycline. Hospital Pharmacy, 2019, 54, 80-87.	0.4	3
88	Remdesivir. Hospital Pharmacy, 2023, 58, 420-430.	0.4	3
89	Perampanel. Hospital Pharmacy, 2013, 48, 321-331.	0.4	3
90	Imatinib mesylate. Reviews in Gastroenterological Disorders, 2002, 2, 75-86.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. Reviews in Gastroenterological Disorders, 2005, 5, 89-100.	0.6	3
92	Pylera plus omeprazole: quadruple treatment for Helicobacter pylori. Reviews in Gastroenterological Disorders, 2008, 8, 33-41.	0.6	3
93	Meloxicam. Hospital Pharmacy, 2000, 35, 852-865.	0.4	2
94	Meperidine: A Drug past its Prime. Hospital Pharmacy, 2001, 36, 1131-1132.	0.4	2
95	Risperidone Long-Acting Injection. Hospital Pharmacy, 2004, 39, 353-363.	0.4	2
96	Parachutes and Evidence-Based Medicine. Hospital Pharmacy, 2004, 39, 618-619.	0.4	2
97	Insulin Detemir. Hospital Pharmacy, 2005, 40, 1062-1074.	0.4	2
98	A Comparison of Educational Methods to Improve NSAID Knowledge and Use of a Medication List in an Elderly Population. Home Health Care Management and Practice, 2005, 17, 403-410.	0.4	2
99	Ramelteon. Hospital Pharmacy, 2006, 41, 59-69.	0.4	2
100	Ibandronate Intravenous. Hospital Pharmacy, 2006, 41, 868-879.	0.4	2
101	New Drugs Approved by the FDA Agents Pending FDA Approval Supplemental Applications Filed by Manufacturer Significant Labeling Changes. Hospital Pharmacy, 2007, 42, 1156-1162.	0.4	2
102	Etravirine. Hospital Pharmacy, 2008, 43, 498-510.	0.4	2
103	Awareness of Risk Evaluation and Mitigation Strategy Program for New Drugs. Hospital Pharmacy, 2009, 44, 208-209.	0.4	2
104	Rufinamide. Hospital Pharmacy, 2009, 44, 412-422.	0.4	2
105	Golimumab. Hospital Pharmacy, 2009, 44, 894-907.	0.4	2
106	The Last Step of the Residency Projects: Publication. Hospital Pharmacy, 2010, 45, 672-673.	0.4	2
107	Acetaminophen Intravenous. Hospital Pharmacy, 2011, 46, 273-285.	0.4	2
108	Deferiprone. Hospital Pharmacy, 2012, 47, 129-136.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Medication Counterfeiting. Hospital Pharmacy, 2014, 49, 683-684.	0.4	2
110	Dolutegravir. Hospital Pharmacy, 2014, 49, 184-195.	0.4	2
111	Ceftolozane/Tazobactam. Hospital Pharmacy, 2015, 50, 526-533.	0.4	2
112	Pharmacy and the "Zombie Apocalypse". Hospital Pharmacy, 2015, 50, 957-958.	0.4	2
113	Surrogate Markers and Drug Approvals. Hospital Pharmacy, 2016, 51, 611-614.	0.4	2
114	Formulary Drug Review: Etelcalcetide. Hospital Pharmacy, 2017, 52, 669-674.	0.4	2
115	Bezlotoxumab. Hospital Pharmacy, 2017, 52, 229-233.	0.4	2
116	Formulary Drug Review: Naldemedine. Hospital Pharmacy, 2017, 52, 464-468.	0.4	2
117	Formulary Drug Review: Safinamide. Hospital Pharmacy, 2017, 52, 532-543.	0.4	2
118	Lefamulin. Hospital Pharmacy, 2022, 57, 704-711.	0.4	2
119	Oritavancin diphosphate. Hospital Pharmacy, 2014, 49, 1049-60.	0.4	2
120	Safety of balsalazide therapy in the treatment of inflammatory bowel disease. Reviews in Gastroenterological Disorders, 2005, 5, 135-41.	0.6	2
121	Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease. Reviews in Gastroenterological Disorders, 2008, 8, 240-53.	0.6	2
122	Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole. Reviews in Gastroenterological Disorders, 2009, 9, E111-8.	0.6	2
123	The Second Generation Sulfonylureas: Glipizide and Glyburide. The Diabetes Educator, 1985, 11, 29-36.	2.6	1
124	Piroxicam "Furosemide Drug Interaction. Drug Intelligence & Clinical Pharmacy, 1988, 22, 505-506.	0.4	1
125	Pharmacy Update. The Diabetes Educator, 1990, 16, 313-316.	2.6	1
126	Paricalcitol Injection and Ribavirin/Interferon Alfa-2b. Hospital Pharmacy, 1999, 34, 303-338.	0.4	1

#	ARTICLE	IF	CITATIONS
127	Direct Measurement of Unfractionated Heparin Using a Biochemical Assay. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 267-276.	0.7	1
128	Zaleplon. <i>Hospital Pharmacy</i> , 2000, 35, 77-86.	0.4	1
129	Pantoprazole IV. <i>Hospital Pharmacy</i> , 2001, 36, 846-855.	0.4	1
130	Formoterol Fumarate Inhalation Powder. <i>Hospital Pharmacy</i> , 2001, 36, 753-767.	0.4	1
131	HIPAA Privacy Rules. <i>Hospital Pharmacy</i> , 2002, 37, 908-910.	0.4	1
132	Icodextrin Peritoneal Dialysis Solution. <i>Hospital Pharmacy</i> , 2003, 38, 669-678.	0.4	1
133	Aprepitant. <i>Hospital Pharmacy</i> , 2003, 38, 763-774.	0.4	1
134	Ezetimibe. <i>Hospital Pharmacy</i> , 2003, 38, 357-366.	0.4	1
135	Adefovir Dipivoxil. <i>Hospital Pharmacy</i> , 2003, 38, 144-154.	0.4	1
136	Improved Access to Information from Clinical Trials with Negative Results. <i>Hospital Pharmacy</i> , 2004, 39, 930-930.	0.4	1
137	Morphine Sulfate Extended-Release Liposome Injection. <i>Hospital Pharmacy</i> , 2004, 39, 871-879.	0.4	1
138	Medication Safety and Radio Frequency Identification Technology. <i>Hospital Pharmacy</i> , 2005, 40, 10-10.	0.4	1
139	Anidulafungin. <i>Hospital Pharmacy</i> , 2006, 41, 669-681.	0.4	1
140	Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine. <i>Hospital Pharmacy</i> , 2006, 41, 1185-1195.	0.4	1
141	Posaconazole Oral Suspension. <i>Hospital Pharmacy</i> , 2007, 42, 57-72.	0.4	1
142	Arformoterol Tartrate. <i>Hospital Pharmacy</i> , 2007, 42, 447-454.	0.4	1
143	Mesalamine. <i>Hospital Pharmacy</i> , 2007, 42, 543-552.	0.4	1
144	Data Supporting the Use of Prescription Medications for Off-Label Indications. <i>Hospital Pharmacy</i> , 2008, 43, 956-957.	0.4	1

#	ARTICLE	IF	CITATIONS
145	Methylalntrexone Bromide, Subcutaneous. Hospital Pharmacy, 2008, 43, 734-743.	0.4	1
146	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug or Biologics License Applications Filed by Manufacturer; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Care Professional" Letters Related to Safety. Hospital Pharmacy, 2009, 44, 340-344.	0.4	1
147	Granisetron Transdermal System. Hospital Pharmacy, 2009, 44, 332-339.	0.4	1
148	Rifaximin. Hospital Pharmacy, 2010, 45, 712-717.	0.4	1
149	Glycopyrrolate Oral Solution. Hospital Pharmacy, 2010, 45, 939-943.	0.4	1
150	Spinosad 0.9% Topical Suspension. Hospital Pharmacy, 2011, 46, 436-440.	0.4	1
151	Dabigatran. Hospital Pharmacy, 2011, 46, 196-207.	0.4	1
152	Glucarpidase. Hospital Pharmacy, 2012, 47, 463-470.	0.4	1
153	Rivaroxaban in Nonvalvular Atrial Fibrillation. Hospital Pharmacy, 2012, 47, 293-304.	0.4	1
154	Nonprescription Drug Safe Use Regulatory Expansion. Hospital Pharmacy, 2013, 48, 448-450.	0.4	1
155	Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Hospital Pharmacy, 2014, 49, 73-96.	0.4	1
156	Insulin Degludec/Liraglutide. Hospital Pharmacy, 2017, 52, 374-380.	0.4	1
157	Formulary Drug Reviews: Plecanatide. Hospital Pharmacy, 2017, 52, 400-405.	0.4	1
158	Formulary Drug Reviews: Glecaprevir/Pibrentasvir. Hospital Pharmacy, 2018, 53, 75-84.	0.4	1
159	Formulary Drug Review: Sufentanil Sublingual. Hospital Pharmacy, 2019, 54, 222-228.	0.4	1
160	Risankizumab. Hospital Pharmacy, 2019, , 001857871987387.	0.4	1
161	Crizanlizumab. Hospital Pharmacy, 2020, , 001857872092537.	0.4	1
162	Cetirizine Hydrochloride Injection. Hospital Pharmacy, 2020, , 001857872091038.	0.4	1

#	ARTICLE	IF	CITATIONS
163	Fostemsavir. Hospital Pharmacy, 0, , 001857872098543.	0.4	1
164	Dasiglucagon. Hospital Pharmacy, 0, , 001857872110468.	0.4	1
165	Retapamulin 1% Ointment. Hospital Pharmacy, 2007, 42, 846-855.	0.4	1
166	Rotigotine Transdermal System. Hospital Pharmacy, 2007, 42, 939-950.	0.4	1
167	Regadenoson Injection. Hospital Pharmacy, 2009, 44, 57-68.	0.4	1
168	Therapeutic equivalence of mesalamine products. Reviews in Gastroenterological Disorders, 2004, 4, 25-8.	0.6	1
169	Trental: A New Medication for Diabetic Peripheral Vascular Disorders. The Diabetes Educator, 1984, 10, 66-66.	2.6	0
170	Risedronate Sodium and Tirofiban Hydrochloride. Hospital Pharmacy, 1999, 34, 207-231.	0.4	0
171	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval Market Withdrawals Major Labeling Changes. Hospital Pharmacy, 1999, 34, 364-374.	0.4	0
172	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval Market Withdrawals Major Labeling Changes. Hospital Pharmacy, 1999, 34, 492-501.	0.4	0
173	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval Market Withdrawals Major Labeling Changes. Hospital Pharmacy, 1999, 34, 579-590.	0.4	0
174	Cilostazol. Hospital Pharmacy, 1999, 34, 859-871.	0.4	0
175	Lopinavir/Ritonavir. Hospital Pharmacy, 2000, 35, 83-92.	0.4	0
176	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Major Labeling Changes. Hospital Pharmacy, 2000, 35, 761-774.	0.4	0
177	Dofetilide. Hospital Pharmacy, 2000, 35, 526-535.	0.4	0
178	Alosetron. Hospital Pharmacy, 2000, 35, 631-638.	0.4	0
179	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Major Labeling Changes. Hospital Pharmacy, 2000, 35, 871-878.	0.4	0
180	Tenecteplase. Hospital Pharmacy, 2000, 35, 1090-1098.	0.4	0

#	ARTICLE	IF	CITATIONS
181	Methylphenidate Extended-Release Tablets. Hospital Pharmacy, 2000, 35, 1319-1327.	0.4	0
182	Insulin Aspart. Hospital Pharmacy, 2000, 35, 1221-1229.	0.4	0
183	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval. Hospital Pharmacy, 2001, 36, 319-325.	0.4	0
184	Almotriptan Malate. Hospital Pharmacy, 2001, 36, 1066-1078.	0.4	0
185	Providing New Safety Information to Prescribers. Hospital Pharmacy, 2001, 36, 242-242.	0.4	0
186	New Drugs Approved by the FDA/New Dosage Forms and Indications/Agents Pending FDA Approval/Labeling Changes Related to Safety. Hospital Pharmacy, 2001, 36, 1096-1111.	0.4	0
187	Do "Dear Health Care Professional" Letters Make a Difference?. Hospital Pharmacy, 2001, 36, 928-928.	0.4	0
188	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval. Hospital Pharmacy, 2001, 36, 664-676.	0.4	0
189	Sodium Phosphate Monobasic Monohydrate, USP and Sodium Phosphate Anhydrous, USP. Hospital Pharmacy, 2001, 36, 306-312.	0.4	0
190	Treprostinil Sodium Injection. Hospital Pharmacy, 2002, 37, 1196-1204.	0.4	0
191	Frovatriptan Succinate. Hospital Pharmacy, 2002, 37, 391-401.	0.4	0
192	The Pharmacy Preceptor: A Critical Link in Pharmacy Education. Hospital Pharmacy, 2002, 37, 576-576.	0.4	0
193	Interferon Beta-1a. Hospital Pharmacy, 2002, 37, 957-966.	0.4	0
194	Ziprasidone Mesylate for Injection. Hospital Pharmacy, 2002, 37, 1307-1317.	0.4	0
195	Drotrecogin Alfa. Hospital Pharmacy, 2002, 37, 511-520.	0.4	0
196	Cefditoren Pivoxil. Hospital Pharmacy, 2002, 37, 274-284.	0.4	0
197	Fondaparinux Sodium. Hospital Pharmacy, 2002, 37, 737-747.	0.4	0
198	Pegfilgrastim. Hospital Pharmacy, 2002, 37, 840-848.	0.4	0

#	ARTICLE	IF	CITATIONS
199	Sound-Alike and Look-Alike Drug Errors. Hospital Pharmacy, 2002, 37, 225-225.	0.4	0
200	Emtricitabine. Hospital Pharmacy, 2003, 38, 1151-1160.	0.4	0
201	Teriparatide. Hospital Pharmacy, 2003, 38, 463-473.	0.4	0
202	Reducing Medication Errors with Prescription Bar Coding. Hospital Pharmacy, 2003, 38, 10-11.	0.4	0
203	Medication Counterfeiting: The Next Form of Terrorism or Just Greed?. Hospital Pharmacy, 2003, 38, 194-195.	0.4	0
204	Pharmacogenomics and Drug Product Labeling. Hospital Pharmacy, 2003, 38, 524-524.	0.4	0
205	Summit Meeting on Pharmaceutical Bar Coding. Hospital Pharmacy, 2003, 38, 817-817.	0.4	0
206	Influenza Virus Vaccine, Live, Intranasal. Hospital Pharmacy, 2003, 38, 947-957.	0.4	0
207	Gemifloxacin Mesylate. Hospital Pharmacy, 2003, 38, 851-861.	0.4	0
208	Rasburicase. Hospital Pharmacy, 2003, 38, 50-57.	0.4	0
209	Ezetimibe/Simvastatin. Hospital Pharmacy, 2004, 39, 1076-1088.	0.4	0
210	Rosuvastatin Calcium. Hospital Pharmacy, 2004, 39, 52-68.	0.4	0
211	Acamprosate Calcium Delayed-Release Tablets. Hospital Pharmacy, 2004, 39, 1177-1188.	0.4	0
212	Memantine. Hospital Pharmacy, 2004, 39, 254-263.	0.4	0
213	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes Related to Safety. Hospital Pharmacy, 2004, 39, 880-894.	0.4	0
214	New Drugs Approved by the FDA: New Dosage Forms and Indications: Agents Pending FDA Approval: Significant Labeling Changes Related to Safety. Hospital Pharmacy, 2004, 39, 1089-1100.	0.4	0
215	Cinacalcet Hydrochloride. Hospital Pharmacy, 2004, 39, 666-680.	0.4	0
216	Peer Review: Personal Continuous Quality Improvement. Hospital Pharmacy, 2004, 39, 8-8.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Olanzapine for Injection (Intramuscular). Hospital Pharmacy, 2004, 39, 776-785.	0.4	0
218	Intravenous N-Acetylcysteine. Hospital Pharmacy, 2004, 39, 564-570.	0.4	0
219	Botulism Immune Globulin Intravenous. Hospital Pharmacy, 2004, 39, 470-477.	0.4	0
220	Tinidazole. Hospital Pharmacy, 2004, 39, 976-987.	0.4	0
221	Pentetate Calcium Trisodium (Ca-DTPA) and Pentetate Zinc Trisodium (Zn-DTPA). Hospital Pharmacy, 2005, 40, 65-71.	0.4	0
222	Entecavir. Hospital Pharmacy, 2005, 40, 798-811.	0.4	0
223	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2005, 40, 614-625.	0.4	0
224	Palifermin. Hospital Pharmacy, 2005, 40, 515-526.	0.4	0
225	Lanthanum Carbonate. Hospital Pharmacy, 2005, 40, 250-261.	0.4	0
226	Tamiflu: Drug Hoarding vs Public Stockpiling. Hospital Pharmacy, 2005, 40, 1027-1027.	0.4	0
227	Metered-Dose Inhalers and the Ozone Layer. Hospital Pharmacy, 2005, 40, 642-642.	0.4	0
228	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes Related to Safety. Hospital Pharmacy, 2005, 40, 170-183.	0.4	0
229	Pramlintide Acetate. Hospital Pharmacy, 2005, 40, 599-613.	0.4	0
230	Exenatide Injection. Hospital Pharmacy, 2005, 40, 994-1003.	0.4	0
231	Eszopiclone. Hospital Pharmacy, 2005, 40, 430-442.	0.4	0
232	Micafungin Sodium. Hospital Pharmacy, 2005, 40, 693-704.	0.4	0
233	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2005, 40, 813-821.	0.4	0
234	Hydromorphone Hydrochloride Extended-Release Capsules (C-II). Hospital Pharmacy, 2005, 40, 156-164.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Over-the-Counter Orlistat. Hospital Pharmacy, 2006, 41, 497-498.	0.4	0
236	New Drugs Approved by the FDA: Agents Pending FDA Approval Supplemental Applications Filed by Manufacturer Significant Labeling Changes. Hospital Pharmacy, 2007, 42, 356-358.	0.4	0
237	Fentanyl Effervescent Buccal Tablet. Hospital Pharmacy, 2007, 42, 230-239.	0.4	0
238	Sitagliptin Phosphate. Hospital Pharmacy, 2007, 42, 133-140.	0.4	0
239	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2007, 42, 141-144.	0.4	0
240	Drug Safety Information. Hospital Pharmacy, 2007, 42, 978-980.	0.4	0
241	New Drugs Approved by the FDA; Agents Pending FDA Approval; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes Baker. Hospital Pharmacy, 2007, 42, 1061-1070.	0.4	0
242	Editorial - Influenza Vaccinations and Back-to-School Shopping. Hospital Pharmacy, 2007, 42, 674-674.	0.4	0
243	Telbivudine. Hospital Pharmacy, 2007, 42, 345-355.	0.4	0
244	Sumatriptan Succinate/Naproxen Sodium. Hospital Pharmacy, 2008, 43, 650-660.	0.4	0
245	Sapropterin Dihydrochloride Tablets. Hospital Pharmacy, 2008, 43, 307-314.	0.4	0
246	New Drugs Approved by the FDA Agents Pending FDA Approval Supplemental Applications Filed by Manufacturer Significant Labeling Changes. Hospital Pharmacy, 2008, 43, 410-418.	0.4	0
247	Certolizumab Pegol. Hospital Pharmacy, 2008, 43, 998-1010.	0.4	0
248	Human Patient Simulation: Is this Included in your List of Job or Residency Interview Questions for New Graduates?. Hospital Pharmacy, 2008, 43, 693-694.	0.4	0
249	Alvimopan. Hospital Pharmacy, 2008, 43, 819-829.	0.4	0
250	New Drugs Approved by the FDA; Agents Pending FDA Approval; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes. Hospital Pharmacy, 2008, 43, 317-322.	0.4	0
251	Raltegravir Potassium. Hospital Pharmacy, 2008, 43, 127-135.	0.4	0
252	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug/Biologics License Applications Filed by Manufacturer; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Care Professional" Letters Related to Safety. Hospital Pharmacy, 2009, 44, 619-622.	0.4	0

#	ARTICLE	IF	CITATIONS
253	Tolvaptan. Hospital Pharmacy, 2009, 44, 998-1009.	0.4	0
254	Dronedarone. Hospital Pharmacy, 2009, 44, 1115-1123.	0.4	0
255	Tenofovir Disoproxil Fumarate Tablets. Hospital Pharmacy, 2009, 44, 165-178.	0.4	0
256	New Drugs Approved by the FDA/New Dosage Forms and Indications Approved by the FDA/Agents Pending FDA Approval/Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2010, 45, 404-417.	0.4	0
257	Buprenorphine Transdermal System. Hospital Pharmacy, 2010, 45, 863-870.	0.4	0
258	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug/Biologics License Applications Filed by Manufacturer; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2010, 45, 496-502.	0.4	0
259	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2010, 45, 567-571.	0.4	0
260	Aztreonam Lysine Inhalation Solution. Hospital Pharmacy, 2010, 45, 634-641.	0.4	0
261	Pegloticase. Hospital Pharmacy, 2011, 46, 41-47.	0.4	0
262	Ceftaroline Fosamil. Hospital Pharmacy, 2011, 46, 349-358.	0.4	0
263	New Drugs Approved by the FDA: New Dosage Forms and Indications Approved by the FDA: Agents Pending FDA Approval: Supplemental Applications Filed by Manufacturer: Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2011, 46, 445-449.	0.4	0
264	Linagliptin. Hospital Pharmacy, 2011, 46, 685-699.	0.4	0
265	Roflumilast. Hospital Pharmacy, 2011, 46, 597-606.	0.4	0
266	Exenatide Extended-Release Injection. Hospital Pharmacy, 2012, 47, 633-644.	0.4	0
267	Biogeneric versus Biosimilar Products. Hospital Pharmacy, 2012, 47, 822-824.	0.4	0
268	Ivermectin 0.5% Topical Lotion. Hospital Pharmacy, 2012, 47, 721-724.	0.4	0
269	Phentermine/Topiramate Extended Release. Hospital Pharmacy, 2012, 47, 950-958.	0.4	0
270	Aflibercept. Hospital Pharmacy, 2012, 47, 375-381.	0.4	0

#	ARTICLE	IF	CITATIONS
271	Lorcaserin Hydrochloride. Hospital Pharmacy, 2012, 47, 871-879.	0.4	0
272	Breakthrough Drug Approval Process and Postmarketing ADR Reporting. Hospital Pharmacy, 2013, 48, 796-798.	0.4	0
273	Legalization of Recreational and Medical Marijuana: What We Don't Know. Hospital Pharmacy, 2014, 49, 319-320.	0.4	0
274	Simeprevir Capsules. Hospital Pharmacy, 2014, 49, 376-389.	0.4	0
275	Ivradradine. Hospital Pharmacy, 2015, 50, 806-817.	0.4	0
276	US Food and Drug Administration Web Site: A Primer for Pharmacists. Hospital Pharmacy, 2015, 50, 985-993.	0.4	0
277	Volunteerism and Professional Development. Hospital Pharmacy, 2015, 50, 655-656.	0.4	0
278	What is your Institution's Position Going to be on Biosimilars?. Hospital Pharmacy, 2015, 50, 435-436.	0.4	0
279	Idarucizumab. Hospital Pharmacy, 2016, 51, 256-262.	0.4	0
280	Rolapitant. Hospital Pharmacy, 2016, 51, 165-175.	0.4	0
281	Fentanyl Iontophoretic Transdermal System. Hospital Pharmacy, 2016, 51, 71-82.	0.4	0
282	Formulary Drug Review: Ocrelizumab. Hospital Pharmacy, 2017, 52, 599-606.	0.4	0
283	For Sale: FDA Priority Review Vouchers. Hospital Pharmacy, 2017, 52, 324-325.	0.4	0
284	Angiotensin II. Hospital Pharmacy, 2018, 53, 230-233.	0.4	0
285	Formulary Drug Reviews: Brexanolone Injection. Hospital Pharmacy, 2019, , 001857871986768.	0.4	0
286	Nasal Glucagon. Hospital Pharmacy, 2019, , 001857871988891.	0.4	0
287	Ferric Derisomaltose. Hospital Pharmacy, 2020, , 001857872094676.	0.4	0
288	Meloxicam Intravenous Injection. Hospital Pharmacy, 0, , 001857872096543.	0.4	0

#	ARTICLE	IF	CITATIONS
289	Oliceridine. Hospital Pharmacy, 0, , 001857872098713.	0.4	0
290	Vericiguat. Hospital Pharmacy, 0, , 001857872110163.	0.4	0
291	Formulary Drug Review: Cabotegravir. Hospital Pharmacy, 0, , 001857872110295.	0.4	0
292	The Implementation of Medicare Part D. Hospital Pharmacy, 2006, 41, 220-220.	0.4	0
293	Insulin Human (rDNA Origin) Inhalation Powder. Hospital Pharmacy, 2006, 41, 560-573.	0.4	0
294	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2006, 41, 683-688.	0.4	0
295	Campaign to Eliminate Use of Error-Prone Abbreviations. Hospital Pharmacy, 2006, 41, 809-810.	0.4	0
296	Formulary Drug Reviews - Ibuprofen Lysine Injection. Hospital Pharmacy, 2006, 41, 970-978.	0.4	0
297	MedWatch's Drug Safety Alert System. Hospital Pharmacy, 2007, 42, 394-395.	0.4	0
298	Maraviroc. Hospital Pharmacy, 2007, 42, 1046-1057.	0.4	0
299	Dexrazoxane. Hospital Pharmacy, 2008, 43, 43-49.	0.4	0
300	Systematic Reviews and Meta-Analyses: "Caveat Emptor"™. Hospital Pharmacy, 2008, 43, 80-80.	0.4	0
301	New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval Significant Labeling Changes or "Dear Health Care Professional" Letters Related to Safety. Hospital Pharmacy, 2009, 44, 423-427.	0.4	0
302	Febuxostat. Hospital Pharmacy, 2009, 44, 688-699.	0.4	0
303	Telavancin. Hospital Pharmacy, 2010, 45, 142-149.	0.4	0
304	Boceprevir and Telaprevir. Hospital Pharmacy, 2011, 46, 779-796.	0.4	0
305	Indacaterol. Hospital Pharmacy, 2012, 47, 219-236.	0.4	0
306	Should the Term "Statistical Significance" and P Values Go Away in Pharmacy Publications?. Hospital Pharmacy, 2012, 47, 420-420.	0.4	0

#	ARTICLE	IF	CITATIONS
307	Ivacaftor. Hospital Pharmacy, 2012, 47, 544-549.	0.4	0
308	Lucinactant. Hospital Pharmacy, 2012, 47, 788-793.	0.4	0
309	Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Hospital Pharmacy, 2012, 47, 798-802.	0.4	0
310	Formulary Drug Review: Odevixibat. Hospital Pharmacy, 0, , 001857872110690.	0.4	0
311	Esomeprazole: update and clinical review. Reviews in Gastroenterological Disorders, 2002, 2, 189-99.	0.6	0
312	Formulary Drug Review: Belumosudil. Hospital Pharmacy, 0, , 001857872110613.	0.4	0
313	Avacopan. Hospital Pharmacy, 0, , 001857872210871.	0.4	0